Denteric

Alzheimer’s disease accounts for 70% of dementia cases. Research suggests chronic inflammation and infections may contribute to its development.

Traditional treatment for periodontitis involves dental visits, deep cleaning, and surgery as the disease progresses.

The Denteric Team are global experts in the field of Porphyromonas gingivalis (Pg) research and vaccine development, located in Australia and the US.

Denteric develops therapies to treat inflammation caused by *Porphyromonas gingivalis* toxins. Its initial therapy targets severe periodontal disease or cases resistant to standard care.

The company was set-up to develop and commercialise the research outputs of a long-running programme originating from the University of Melbourne working in collaboration with CSL.

Recent success with Pfizer and Moderna vaccines to Covid-19 has proven efficacy of mRNA vaccines for viruses, but little is known about using mRNA against bacterial pathogens, which are equally abundant.

The Brandon BioCatalyst incubator received $40 million from Australia’s Medical Research Future Fund. It may offer follow-on investment from its $800 million life sciences fund, and CSIRO contributed $3 million to CUREator.

Denteric dosed its first subjects in a safety study of GPV381, a therapy for severe periodontal disease.

Denteric is developing a novel therapy called GPV381 for chronic inflammation. Initially treating periodontitis in patients with severe or refractory disease, GPV381 targets the toxins of a bacterium called Porphyromonas gingivalis.

Denteric’s privacy policy outlines its obligations regarding the management of personal information.